Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Booth

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimenJohn R Johnson, Martin Cohen, Rajeshwari Sridhara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHDKelly J Norsworthy, Donna R Rivera, Joseph Wynne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinibMaitreyee Hazarika, Xiaoping Jiang, Qi Liu, et al.
The AAPS Journal|January 1, 2015
Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidanceBrian Booth, Mark E Arnold, Binodh DeSilva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 MutationAshley C Woods, Kelly J Norsworthy, Moran Choe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateMichael Brave, Vicki Goodman, Edvardas Kaminskas, et al.
Clinical Pharmacology and Therapeutics|February 15, 2023
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial DataQi Liu, Raina Mathur, Yuan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent AnemiaNina Kim, E Dianne Pulte, Lori A Ehrlich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summaryKatherine Thornton, Geoffrey Kim, V Ellen Maher, et al.
Clinical Pharmacology and Therapeutics|June 5, 2025
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology DrugsWei Gao, Jiang Liu, Cynthia J Musante, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimenJohn R Johnson, Martin Cohen, Rajeshwari Sridhara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHDKelly J Norsworthy, Donna R Rivera, Joseph Wynne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinibMaitreyee Hazarika, Xiaoping Jiang, Qi Liu, et al.
The AAPS Journal|January 1, 2015
Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidanceBrian Booth, Mark E Arnold, Binodh DeSilva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 MutationAshley C Woods, Kelly J Norsworthy, Moran Choe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateMichael Brave, Vicki Goodman, Edvardas Kaminskas, et al.
Clinical Pharmacology and Therapeutics|February 15, 2023
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial DataQi Liu, Raina Mathur, Yuan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent AnemiaNina Kim, E Dianne Pulte, Lori A Ehrlich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summaryKatherine Thornton, Geoffrey Kim, V Ellen Maher, et al.
Clinical Pharmacology and Therapeutics|June 5, 2025
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology DrugsWei Gao, Jiang Liu, Cynthia J Musante, et al.
Pageof 5